COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects

Xiao Hu, Shulian Shang, Ivan Nestorov, Jawad Hasan, Ali Seddighzadeh, Katherine Dawson, Bjørn Sperling, Brian Werneburg, Xiao Hu, Shulian Shang, Ivan Nestorov, Jawad Hasan, Ali Seddighzadeh, Katherine Dawson, Bjørn Sperling, Brian Werneburg

Abstract

Aim: Subcutaneous (s.c.) peginterferon beta-1a injected once every 2 weeks and s.c. interferon beta-1a injected three times per week (Rebif®) have demonstrated efficacy in relapsing-remitting multiple sclerosis, but direct comparisons of pharmacological activity and tolerability between the two products are lacking. COMPARE was an open label, crossover, pharmacokinetic (PK) study evaluating drug exposure and the safety and tolerability of s.c. peginterferon beta-1a and s.c. interferon beta-1a, over 2 weeks in healthy subjects.

Methods: Thirty healthy subjects received one dose of peginterferon beta-1a (125 μg s.c.) or six doses of interferon beta-1a (44 μg s.c.) over 2 weeks, followed by the alternate treatment after a 2 week washout period. Drug concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) and PK parameters including cumulative area under the concentration-time curve (AUC0-336h ) over 2 weeks and maximum observed serum concentrations (Cmax ) were estimated using a non-compartmental analysis.

Results: The PK analysis population comprised 26 subjects for each treatment. Drug exposure (AUC0-336h ) was 60% higher with s.c. peginterferon than with s.c. interferon beta-1a (117.4 ng ml(-1) h, 95% confidence interval 95.6, 144.3 vs. 73.1 ng ml(-1) h, 95% confidence interval 61.2, 87.3, respectively; P < 0.0001). Injection-site reactions (ISRs) were the most common adverse events (AEs) observed with both treatments. Numerically lower frequencies and incidence rates of ISRs, headache, myalgia and chills were observed with s.c. peginterferon beta-1a.

Conclusions: One dose of s.c. peginterferon delivered significantly greater drug exposure than s.c. interferon beta-1a three times a week over 2 weeks, and a lower frequency of AEs.

Trial registration: ClinicalTrials.gov NCT02269930.

Keywords: AUC; exposure; injection-site reactions; multiple sclerosis; pharmacokinetics; tolerability.

© 2016 The British Pharmacological Society.

Figures

Figure 1
Figure 1
Study design. S.c. subcutaneous
Figure 2
Figure 2
Peginterferon beta‐1a and interferon beta‐1a serum concentration ±SE over 2 weeks. Dashed lines represent lower limit of quantification (15 pg ml–1 for s.c. peginterferon beta‐1a; 6 pg ml–1 for s.c. interferon beta‐1a); *n = 27 for doses 1–4 and n = 26 for doses 5–6. S.c., subcutaneous; SE, standard error. s.c. peginterferon beta‐1a (n = 26), s.c interferon beta‐1a (n = 26–27*)
Figure 3
Figure 3
Incidence (A) and frequency (B) of AEs related to study drug occuring in >10% of subjects following either treatment () s.c. peginterferon beta‐1a (n = 29), () s.c. interferon beta‐1a (n = 29). AE, adverse event; s.c., subcutaneous

References

    1. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon β‐1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double‐blind study. Lancet Neurol 2014; 13: 657–65.
    1. Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, et al. Peginterferon beta‐1a in multiple sclerosis: 2‐year results from ADVANCE. Mult Scler 2015; 21: 1025–35.
    1. Kieseier BC, Calabresi PA. PEGylation of interferon‐beta‐1a: a promising strategy in multiple sclerosis. CNS Drugs 2012; 26: 205–14.
    1. Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, et al. N‐terminally PEGylated human interferon‐beta‐1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 2006; 17: 179–88.
    1. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, et al. A novel PEGylated interferon beta‐1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 2012; 52: 798–808.
    1. Plegridy Prescribing Information . Available at: (last accessed 16 September 2015).
    1. Rebif Prescribing Information . Available at: (last accessed 16 September 2015).
    1. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN‐beta 1a in healthy volunteers. J Interferon Cytokine Res 2000; 20: 857–66.
    1. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169–78.
    1. European Medicines Agency . Plegridy: Summary of Product Characteristics. 2014. Available at: (last accessed 11 September 2015).
    1. Abuarjah K, Gonzalez E, Mancino A, O′Toole K, Desai H, Beaver C. Optimization and validation of an ELISA kit for the quantification of four interferon‐beta (IFN‐ß) marketed compounds in human serum. inVentiv Health (PBL) poster presented at the AAPS Annual Meeting, Chicago, IL, USA, October 14–18, 2012.
    1. PRISMS (Prevention of Relapses and Disability by Interferon beta‐1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double‐blind placebo‐controlled study of interferon beta‐1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta‐1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498–504.
    1. European Medicines Agency . Rebif: Summary of Product Characteristics. 1998. Availalble at: (last accessed 11 September 2015).
    1. Hu X, Cui Y, White J, Zhu Y, Deykin A, Nestorov I, et al. Pharmacokinetics and pharmacodynamics of peginterferon beta‐1a in patients with relapsing–remitting multiple sclerosis in the randomized ADVANCE study. Br J Clin Pharmacol 2015; 79: 514–22.
    1. White JT, Crossman M, Richter K, Berman M, Goyal J, Subramanyam M. Immunogenicity evaluation strategy for a second generation therapeutic, peginterferon beta‐1a. Bioanalysis 2015; 7: 2801–11
    1. Garay RP, El‐Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG‐conjugated agents. Expert Opin Drug Deliv 2012; 9: 1319–23.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner